Your browser doesn't support javascript.
loading
Advances in metformin-delivery systems for diabetes and obesity management.
Abbasi, Mehrnaz; Heath, Braeden; McGinness, Lauren.
Afiliação
  • Abbasi M; Department of Nutritional Sciences, College of Human Sciences, Auburn University, Auburn, Alabama, USA.
  • Heath B; Department of Biomedical Sciences, College of Sciences and Mathematics, Auburn University, Auburn, Alabama, USA.
  • McGinness L; Department of Nutritional Sciences, College of Human Sciences, Auburn University, Auburn, Alabama, USA.
Diabetes Obes Metab ; 26(9): 3513-3529, 2024 Sep.
Article em En | MEDLINE | ID: mdl-38984380
ABSTRACT
Metformin is a medication that is commonly prescribed to manage type 2 diabetes. It has been used for more than 60 years and is highly effective in lowering blood glucose levels. Recent studies indicate that metformin may have additional medical benefits beyond treating diabetes, revealing its potential therapeutic uses. Oral medication is commonly used to administer metformin because of its convenience and cost-effectiveness. However, there are challenges in optimizing its effectiveness. Gastrointestinal side effects and limitations in bioavailability have led to the underutilization of metformin. Innovative drug-delivery systems such as fast-dissolving tablets, micro/nanoparticle formulations, hydrogel and microneedles have been explored to optimize metformin therapy. These strategies enhance metformin dosage, targeting, bioavailability and stability, and provide personalized treatment options for improved glucose homeostasis, antiobesity and metabolic health benefits. Developing new delivery systems for metformin shows potential for improving therapeutic outcomes, broadening its applications beyond diabetes management and addressing unmet medical needs in various clinical settings. However, it is important to improve drug-delivery systems, addressing issues such as complexity, cost, biocompatibility, stability during storage and transportation, loading capacity, required technologies and biomaterials, targeting precision and regulatory approval. Addressing these limitations is crucial for effective, safe and accessible drug delivery in clinical practice. In this review, recent advances in the development and application of metformin-delivery systems for diabetes and obesity are discussed.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sistemas de Liberação de Medicamentos / Diabetes Mellitus Tipo 2 / Hipoglicemiantes / Metformina / Obesidade Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sistemas de Liberação de Medicamentos / Diabetes Mellitus Tipo 2 / Hipoglicemiantes / Metformina / Obesidade Idioma: En Ano de publicação: 2024 Tipo de documento: Article